Foamy virus vectors for suicide gene therapy

Gene Therapy

Volumn 4, Issue 11, 1997, Pages 1270-1277

  Nestler, U ^a,b   Heinkelein, M ^a   Lucke M ^a   Meixensberger, J ^b   Scheurlen, W ^a,e   Kretschmer, A ^c   Rethwilm, A ^a,d  

^a UNIVERSITY OF WÜRZBURG   (Germany)

^b Neurochirurgische Univ Klin   (Germany)

^c BAYER AG   (Germany)

^d UNIVERSITY OF WÜRZBURG   (Germany)

^e UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Cytosine deaminase; Foamy virus vectors; Polynucleoside phosphatase; Suicide gene therapy; Thymidine kinase

Indexed keywords

CYTOSINE DEAMINASE; PHOSPHORYLASE; THYMIDINE KINASE; VIRUS VECTOR;

ANIMAL CELL; ARTICLE; CANCER THERAPY; CELL KILLING; CELL STRAIN BHK; CONTROLLED STUDY; GENE EXPRESSION; GENE FUNCTION; GENE TARGETING; GENE THERAPY; GENETIC TRANSDUCTION; HERPES SIMPLEX VIRUS 1; IMMUNOBLOTTING; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SOLID TUMOR; SPUMA VIRUS; SUICIDE GENE; TUMOR CELL; VIRUS RECOMBINANT;

ANIMALIA; HERPES; HERPES VIRUS TYPE 1; HERPESVIRIDAE; HUMAN HERPESVIRUS 1; HUMAN SPUMARETROVIRUS; SPUMAVIRUS;

EID: 0030831840     PISSN: 09697128     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.gt.3300561     Document Type: Article

References (28)

1. Deonarian MI, Spooner RA, Epenetos AA. Genetic delivery of enzymes for cancer therapy. Gene Therapy 1995; 2: 235-244.
2. Sikora K. Genetic approaches to cancer gene therapy. Gene Therapy 1994; 1: 149-151.
3. Culver KW et al. In vivo gene transfer with retroviral vectorproducer cells for treatment of experimental brain tumor. Science 1992; 256: 1550-1552.
4. Bieniasz PD et al. Comparative study of higher primate foamy viruses, including a new virus from a gorilla. Virology 1995; 207: 217-228.
5. Herchenroder O et al. Isolation, cloning, and sequencing of simian foamy viruses from chimpanzee (SFVcpz): high homology to human foamy virus (HFV). Virology 1994; 201: 187-199.
6. Rethwilm A. Regulation of foamy virus gene expression. Curr Top Microbiol Immunol 1995; 193: 1-24.
7. Bieniasz PD, Weiss RA, McClure MO. Cell cycle dependence of foamy retrovirus infection. J Virol 1995; 69: 7295-7299.
8. Ali M et al. No evidence of antibody to human foamy virus in widespread human populations. AIDS Res Hum Retrovir 1996; 12: 1473-1483.
9. Schweizer M et al. Markers of foamy virus infections in monkeys, apes, and accidentally infected humans: appropriate testing fails to confirm suspected foamy virus prevalence in humans. AIDS Res Hum Retrovir 1995; 11: 161-170.
10. Schweizer M et al. Simian foamy virus isolated from an accidentally infected human individual. J Virol 1997; 71: 4821-4824.
11. Center for Disease Control. Nonhuman primate spurnavirus infections among persons with occupational exposure. Morbidity and Mortality Weekly Report. 1997; 46: 129-131.
12. Aguzzi A, Marino S, Tschopp R, Rethwilm A. Regulation of expression and pathogenic potential of human foamy virus in vitro and in transgenic mice. Curr Top Microbiol Immunal 1996; 206: 243-273.
13. Bothe K et al. Progressive encephalopathy and myopathy in transgenic mice expressing human foamy virus genes. Science 1991; 253: 555-557.
14. Baunach G et al. Functional analysis of human foamy virus accessory reading frames. J Virol 1993; 67: 5411-5418.
15. Tschopp RR et al. Analysis of the determinants of neurotropism and neurotoxicity of HFV in transgenic mice. Virology 1996; 216: 338-346.
16. Schmidt M, Rethwilm A. Replicating foamy virus-based vectors directing high level expression of foreign genes. Virology 1995; 210: 167-178.
17. Schmidt M, Herchenröder O, Heeney J, Rethwilm A. Long terminal repeat U3 length polymorphism of human foamy virus. Virology 1997; 230: 167-178.
18. Muranyi W, Flügel RM. Analysis of splicing patterns of human spumaretrovirus by polymerase chain reaction reveals complex RNA structures. J Virol 1991; 65: 727-735.
19. Rethwilm A et al. The transcriptional transactivator of human foamy virus maps to the bel-1 genomic region. Proc Natl Acad Sci USA 1991; 88: 941-945.
20. Denizot F, Lang R. Rapid colorimetric assay for cell growth and survival: modifications to the terrazolium dye procedure giving improved sensitivity and reliability. J Immunol Meth 1986; 89: 271-277.
21. Parthasarathi S et al. Genetic rearrangements occurring during a single cycle of murine leukemia virus vector replication: characterization and implications. J Virol 1995; 69: 7991-8000.
22. Giavedoni LD, Yilma T. Construction and characterization of replication-competent simian immunodeficiency virus vectors that express gamma interferon. J Virol 1996; 70: 2247-2251.
23. Gundlach BR et al. Construction, replication, and immunogenic properties of a simian immunodeficiency virus expressing interleukin 2. J Virol 1997; 71: 2225-2232.
24. Hughes BW et al. Bystander killing of melanoma cells using the human tyrosine promoter to express the Escherichia coli purine nucleoside phosphorylase gene. Cancer Res 1995; 55: 3339-3345.
25. Sorscher EJ et al. Tumor cell bystander killing in colonie carcinoma utilizing the Escherichia coli DeoD gene to generate toxic purines. Gene Therapy 1994; 1: 233-238.
26. Dilber MS, Smith CIE. Suicide genes and bystander killing: local and distant effects. Gene Therapy 1997; 4: 273-274.
27. Cole CN, Stacy TP. Identification of sequences in the herpes simplex virus thymidine kinase gene required for efficient processing and polyadenylation. Mol Cell Biol 1985; 5: 2104-2113.
28. Haack et al. Detection of cytosine deaminase in genetically modified tumor cells by specific antibodies. Hum Gene Ther (in press).